Other MSA and Neurology Research

Research news from around the world…

Aug 2025: ASPIRE multi-modal biomarker study to better understand how MSA progresses and identify who may deteriorate more quickly

Mar 2025: Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy 

Dec 2024: MSA: advances in pathophysiology, diagnosis, and treatment

Nov 2024: A case report of Lee Silverman Speech Therapy in MSA 

Oct 2024: Potential Promise Behind ATH434 for Multiple System Atrophy

Jun 2024: New blood test to detect Parkinson’s Disease being researched

Jun 2024: Cambridge Biomedical Research Centre videos – Patient and Public Involvement in research 

Apr 2024: Skin biopsy as a potential method towards a test for Parkinson’s

Strain of gut bacteria contributes to the development of Parkinson’s disease

Researchers in Wales are leading the way in the development of new ways of diagnosing Parkinson’s Disease (PD) and Parkinson’s Disease Dementia (PDD)

Eye scans can detect Parkinsons disease

Promising early results from Parkinson’s vaccine study | Parkinson’s UK (parkinsons.org.uk)

AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)

TENS Shows Promise for Obstructive Sleep Apnoea Treatment

Practical Neurology Multiple System Atrophy Podcast with Dr Chelban and Dr Yee Yen Goh

A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson’s Disease

Study traces cystitis contribution to neurological disorder MSA. Read the full article here.

Researchers have developed a novel assay that can not only reliably detect α-synuclein aggregates, but also differentiate between neurodegenerative diseases – Sowing the seeds of diagnosis: a novel assay for abnormal α-synuclein detection. The full article is available here

Health related quality-of-life and burden for caregivers of individuals with neurogenic orthostatic hypotension

Multiple system atrophy: α-Synuclein strains at the neuron-oligodendrocyte crossroad

Nigral glucose metabolism as a diagnostic marker of neurodegenerative parkinsonian syndromes

Identical structures of α-synuclein filaments from Parkinson’s disease and dementia with Lewy bodies

Woman who can ‘smell Parkinson’s’ helps scientists come up with breakthrough diagnostic test

Journal of Parkinson’s Disease Journal article, ‘Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?’

Researchers from the University of Florida will begin testing a new artificial intelligence tool that can help distinguish a precise diagnosis between Parkinson’s Disease, Multiple System Atrophy Parkinsonian variant (MSA-P), or Progressive Supranuclear Palsy (PSP)

New Study to Evaluate Mesenchymal Stem Cells to Treat MSA in USA 

Modag has secured funding to take anle138b into the clinic in MSA

Lundbeck have announced a phase II trial – the AMULET research study – which will be recruiting a small number of people with MSA in the US and Japan 

Further information about AMULET trial is available here 

PET scan algorithm has potential to diagnose Parkinson’s, MSA and PSP

Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH) :: Theravance Biopharma

Alterity receives MHRA authorisation for Phase II trial of MSA therapy (clinicaltrialsarena.com)

Spinal implant helps with blood pressure symptoms in MSA 

ERN-RND webinar: “New MDS criteria for clinical diagnosis of MSA” – presented recently via webinar and will be published later in 2022

AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference, and Potential In First for the Field, α-Synuclein PET. Only for Multiple System Atrophy | ALZFORUM

Exploring the benefits and barriers to Nordic walking in people with Parkinson’s disease: a feasibility study

The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy

Lundbeck launches a phase II study for potential new treatment of multiple system atrophy

Alpha-synuclein Test May Aid Earlier Diagnosis

EmeraMed builds momentum in rare disease. EmeraMed’s emeramide saw its PTSR in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) rise by nine points each after a Phase II trial was completed. The PTSR in PSP currently sits at 27% while that in MSA is now 56%. PSP and MSA are both atypical forms of Parkinson’s disease. The Phase II placebo-controlled crossover study (NCT04184063) evaluating the drug’s effect on symptoms and health-related quality of life over 28 days enrolled 20 patients with PSP or MSA. Emermaide, also known as NBMI, is an oral isophthalamide derivative that can prevent oxidative damage and reduce disease toxicity. The study completion, which was posted to ClinicalTrials.gov on 23 September, resulted in a modest one-point bump to the drug’s LoA in MSA to 2%, but there was no LoA change in PSP, which remained at 1%. EmeraMed is headquartered in Ireland and also operates in the US and Sweden. Read more about the trial on the ClinicalTrials.gov website 

Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 (prnewswire.com)  See the conference poster here 

Here is a podcast by Dr Camille Carroll Associate Professor and Honorary Consultant Neurologist Peninsula Medical School (Faculty of Health), NSL for Neurology NIHR CRN, talking about The role of digital, technology, such as sensors and wearables, in clinical trials

Research project ‘Abdominal Binders to Treat Orthostatic Hypotension in Multiple System Atrophy’ receives additional funding

The full publication ‘ATH434 Reduces a-Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy’ on the Movement Disorders Journal website

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Researchers move closer to a test that can sniff out Parkinson’s

Creating drugs to restore mitochondria and stop Parkinson’s

Parkinson’s results beyond researchers’ wildest dreams

The MSA Coalition (USA) research news and therapeutic pipeline summary